Logo image
Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study
Journal article   Open access   Peer reviewed

Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study

Stephanie M Hunn, Lindsay N Alfano, Aileen Jones, Amanda Butler, Linda P Lowes, Megan A Iammarino, Natalie F Reash, Lindsay Pietruszewski, Sandhya Sasidharan, Melissa Currence, …
Annals of clinical and translational neurology, Vol.12(6), pp.1179-1186
06/2025
DOI: 10.1002/acn3.70049
PMCID: PMC12172116
PMID: 40237364
url
https://doi.org/10.1002/acn3.70049View
Published (Version of record) Open Access

Abstract

Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials. Through the Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP-LGMD) Consortium, 42 subjects with LGMDR1 were enrolled in a 12-month natural history study across 11 international sites. Each subject completed a battery of clinical outcome assessments (COA), including the North Star Assessment for Limb Girdle-Type Dystrophies (NSAD), 10-m walk/run, and Performance of the Upper Limb (PUL), in addition to several patient-reported outcome measures (PROM). In this baseline cross-sectional analysis, significant correlations were found between COAs and PROMs, with significant differences in the performance of assessments based on subjects' ambulatory status and genetic variant classification. The study has determined that the NSAD and other assessments are valid and reliable measures for quantifying the level of disease impairment in individuals with LGMDR1.
Natural History limb girdle muscular dystrophy outcome measures

Details

Metrics

Logo image